PL239843B1 - 3β-Hydroxy-17a-oxa-D-homo-B-norandrost-5-en-17-one and method of preparing 3β-hydroxy-17a-oxa-D-homo-B-norandrost-5-en-17-one - Google Patents
3β-Hydroxy-17a-oxa-D-homo-B-norandrost-5-en-17-one and method of preparing 3β-hydroxy-17a-oxa-D-homo-B-norandrost-5-en-17-one Download PDFInfo
- Publication number
- PL239843B1 PL239843B1 PL429380A PL42938019A PL239843B1 PL 239843 B1 PL239843 B1 PL 239843B1 PL 429380 A PL429380 A PL 429380A PL 42938019 A PL42938019 A PL 42938019A PL 239843 B1 PL239843 B1 PL 239843B1
- Authority
- PL
- Poland
- Prior art keywords
- homo
- oxa
- hydroxy
- norandrost
- chloroform
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J69/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one atom and expansion of only one ring by one atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
- C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
- C07J73/003—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P33/00—Preparation of steroids
- C12P33/06—Hydroxylating
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P33/00—Preparation of steroids
- C12P33/12—Acting on D ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P33/00—Preparation of steroids
- C12P33/20—Preparation of steroids containing heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Wynalazek dotyczy 3ß-hydroksy-17a-oksa-D-homo-B-norandrost-5-en-17-onu i sposobu wytwarzania 3ß-hydroksy-17a-oksa-D-homo-B-norandrost-5-en-17-onu. Postępując zgodnie z wynalazkiem, w wyniku działania układu enzymatycznego zawartego w komórkach szczepu Beauvera bassiana KCH1065 na octan B-nor-dehydroepiandrosteronu, o wzorze 1, następuje hydroliza wiązania estrowego oraz utlenienie typu Baeyera-Villigera grupy karbonylowej substratu do laktonu, o wzorze 2. Uzyskany w ten sposób produkt wydziela się z wodnej kultury mikroorganizmu, znanym sposobem, przez ekstrakcję rozpuszczalnikiem organicznym niemieszającym się z wodą (chloroform) i oczyszcza chromatograficznie.The invention relates to 3ß-hydroxy-17a-oxa-D-homo-B-norandrost-5-en-17-one and a method for producing 3ß-hydroxy-17a-oxa-D-homo-B-norandrost-5-en-17- he. Proceeding in accordance with the invention, as a result of the action of the enzymatic system contained in the cells of the Beauvera bassiana KCH1065 strain on B-nor-dehydroepiandrosterone acetate, of formula 1, the ester bond is hydrolyzed and the carbonyl group of the substrate is oxidized by Baeyer-Villiger type to lactone, of formula 2. Obtained in this way, the product is isolated from the aqueous culture of the microorganism, in a known way, by extraction with an organic solvent immiscible with water (chloroform) and purified by chromatography.
Description
PL 239 843 B1PL 239 843 B1
Opis wynalazkuDescription of the invention
Przedmiotem wynalazku jest 3e-hydroksy-17a-oksa-D-homo-B-norandrost-5-en-17-on i sposób wytwarzania 3e-hydroksy-17a-oksa-D- homo-B-norandrost-5-en-17-onu.The present invention relates to 3e-hydroxy-17a-oxa-D-homo-B-norandrost-5-en-17-one and a method for the preparation of 3e-hydroxy-17a-oxa-D-homo-B-norandrost-5-en-17 -on.
Sposobem według wynalazku, można otrzymać steroidowy lakton - B-nor strukturalny analog antynowotworowego i antyandrogennego testolaktonu, o potencjalnie podobnej aktywności. Może on znaleźć wykorzystanie w wytwarzaniu terapeutyków stosowanych w leczeniu chorób hormonozależnych.By the method of the invention, the steroidal lactone B-nor structural analog of anti-tumor and anti-androgen testolactone with potentially similar activity can be obtained. It may find application in the production of therapeutics used in the treatment of hormone-dependent diseases.
Układy steroidowe z ugrupowaniem laktonowym w pierścieniu D wykazują różnorodną aktywność biologiczną. Jako inhibitory 5a-reduktazy - enzymu odpowiedzialnego za przekształcenie testosteronu do 5a-dihydrotestosteronu, mogą być stosowane w terapii chorób androgenozależnych takich jak łagodny przerost prostaty, trądzik, łysienie typu męskiego (M. Garrido, E. Bratoeff, D. Bonilla, J. Soriano, Y. Heuze, M. Cabeza. 2011. New steroidal lactones as 5a-reductase inhibitors and antagonists for the androgen receptor. Journal of Steroid Biochemistry and Molcular Biology, 127, 367-373). Mogą również inhibować aktywność steroidowej aromatazy - enzymu przekształcającego testosteron do estradiolu, tym samym ograniczając syntezę estronu. Ma to znaczenie w terapii zaburzeń równowagi hormonalnej, której skutkiem jest ginekomastia lub przedwczesne dojrzewanie (G.D. Braunstein. 1999. Aromatase and gynecomastia. Endocrine-Related Cancer, 6, 315-324; P. Feuillan, D. Merke, E.W. Leschek., G.B. Cutler. 1999. Use of aromatase inhibitors in precocious puberty. Endocrine-Related Cancer, 6, 303306). Steroidowy testolakton stosowany jest w klinicznym leczeniu zaawansowanego stadium raka piersi (H.M Brodie, V.C.O. Njar. 1998. Aromatase inhibitors In advanced breast cancer: Mechanism of action and implications. Journal of Steroid Biochemistry and Molecular Biology, 66, 1-10; J. Balunas, B. Su, R.W. Brueggemeier, A.D. Kinghorn. 2008. Natural products as aromatase inhibitors. Anticancer Agents in Medicinal Chemistry, 8, 646-682). Modyfikacja szkieletu steroidowego związana z kontrakcją pierścienia B, zwykle nie zmienia aktywności biologicznej takich cząsteczek w stosunku do ich naturalnych kongenerów. Jednakże aktywność hormonalna B-nor analogów testosteronu czy dehydroepiandrosteronu jest znacząco niższa (S.R. Ramadas, P.K. Sujeeth, T.R. Kasturi, F.M. Abraham. 1976. Chemistry & Biological activity of B-norsterods. Journal of Scientific & Industrial Research, 35, 571-586), a związki te uważane są za antyandrogeny - substancje zmniejszające oddziaływanie męskich hormonów na organizm.Steroid systems with a lactone moiety in the D-ring exhibit a variety of biological activities. As inhibitors of 5a-reductase - an enzyme responsible for the conversion of testosterone to 5a-dihydrotestosterone, they can be used in the treatment of androgen-dependent diseases such as benign prostatic hyperplasia, acne, male pattern baldness (M. Garrido, E. Bratoeff, D. Bonilla, J. Soriano , Y. Heuze, M. Cabeza. 2011. New steroidal lactones as 5a-reductase inhibitors and antagonists for the androgen receptor. Journal of Steroid Biochemistry and Molcular Biology, 127, 367-373). They can also inhibit the activity of the steroidal aromatase - the enzyme that converts testosterone to estradiol, thereby limiting the synthesis of estrone. This is of importance in the treatment of hormonal imbalances resulting in gynecomastia or premature puberty (G.D. Braunstein. 1999. Aromatase and gynecomastia. Endocrine-Related Cancer, 6, 315-324; P. Feuillan, D. Merke, E.W. Leschek., G.B. Cutler. 1999. Use of aromatase inhibitors in precocious puberty. Endocrine-Related Cancer, 6, 303306). Steroid testolactone is used in the clinical treatment of advanced breast cancer (H.M Brodie, V.C.O. Njar. 1998. Aromatase inhibitors In advanced breast cancer: Mechanism of action and implications. Journal of Steroid Biochemistry and Molecular Biology, 66, 1-10; J. Balunas) , B. Su, R.W. Brueggemeier, A.D. Kinghorn. 2008. Natural products as aromatase inhibitors. Anticancer Agents in Medicinal Chemistry, 8, 646-682). Modification of the steroid backbone associated with B-ring contraction usually does not alter the biological activity of such molecules relative to their natural congeners. However, the hormonal activity of B-nor analogs of testosterone or dehydroepiandrosterone is significantly lower (S.R. Ramadas, P.K. Sujeeth, T.R. Kasturi, F.M. Abraham. 1976. Chemistry & Biological activity of B-norsterods. Journal of Scientific & Industrial Research, 35, 571-586) , and these compounds are considered antiandrogens - substances that reduce the effect of male hormones on the body.
Chemiczny sposób otrzymywania steroidowych laktonów w reakcji utlenienia typu Baeyera-Villigera grupy karbonylowej substratów za pomocą nadkwasów napotyka szereg utrudnień. Jednym z nich jest toksyczność i niestabilność stosowanych utleniaczy oraz ich skłonność do eksplozji, co dla procesów prowadzonych w skali przemysłowej w połączeniu z wykorzystywanymi w reakcji palnymi rozpuszczalnikami, jest szczególnie istotne. Ważne jest również powstawanie produktów ubocznych w reakcjach, w których substratem jest związek zawierający inne wrażliwe na utlenianie grupy funkcyjne (np. nadkwasy utleniają także wiązanie podwójne). Produkty uboczne powstają również w reakcjach, w których jako czynnik utleniający stosuje się sól magnezową kwasu mononadftalowego (MMPP). Przyjazną dla środowiska alternatywą staje się więc selektywne utlenianie enzymatyczne.The chemical method of obtaining steroid lactones in the Baeyer-Villiger type oxidation of the carbonyl group of substrates with peracids faces a number of difficulties. One of them is the toxicity and instability of the oxidants used and their tendency to explosion, which is particularly important for processes carried out on an industrial scale in combination with flammable solvents used in the reaction. Also important is the formation of by-products in reactions where the substrate is a compound containing other oxidation-sensitive functional groups (e.g. peracids also oxidize a double bond). By-products are also formed in reactions in which the magnesium salt of monoperphthalic acid (MMPP) is used as the oxidizing agent. Thus, selective enzymatic oxidation becomes an environmentally friendly alternative.
W literaturze nie ma doniesień dotyczących otrzymywania 3e-hydroksy-17a-oksa-D-homo-B-norandost-5-en-17-onu, zarówno metodą utleniania enzymatycznego jak i chemicznego.There are no reports in the literature on the preparation of 3e-hydroxy-17a-oxa-D-homo-B-norandost-5-en-17-one, either by enzymatic or chemical oxidation.
Szczep Beauveria bassiana KCH1065 był wcześniej ujawniony w literaturze (A. Świzdor, T. Kotek, A. Panek, A. Białońska, 2011. Microbial Baeyer-Villiger oxidation of steroidal ketones using Beauveria bassiana: Presence of an 11a-hydroxyl group essentials to generation of D-homo lactones. Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, 1811,253-256; A. Świzdor, A. Panek, N. MileckaTronina, 2014. Microbial Baeyer-Villiger oxidation of 5a-steroids using Beauveria bassiana. A stereochemical requirement for the 11a-hydroxylation and the lactonization pathway. Steroids, 82, 44-52).The Beauveria bassiana KCH1065 strain was previously disclosed in the literature (A. Świzdor, T. Kotek, A. Panek, A. Białońska, 2011. Microbial Baeyer-Villiger oxidation of steroidal ketones using Beauveria bassiana: Presence of an 11a-hydroxyl group essentials to generation of D-homo lactones. Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, 1811, 253-256; A. Świzdor, A. Panek, N. MileckaTronina, 2014. Microbial Baeyer-Villiger oxidation of 5a-steroids using Beauveria bassiana A stereochemical requirement for the 11a-hydroxylation and the lactonization pathway. Steroids, 82, 44-52).
Z opisów patentowych PL214913 oraz PL215117, znane są jego biokatalityczne właściwości w jednoczesnej reakcji utlenienia typu Beayera-Villigera oraz 11a-hydroksylacji szeregu steroidów typu androstanu do odpowiednich 11a-hydroksylakonów.From patents PL214913 and PL215117, its biocatalytic properties are known in the simultaneous oxidation reaction of the Beayer-Villiger type and the 11a-hydroxylation of a number of androstane-type steroids to the corresponding 11a-hydroxylacones.
Istotą wynalazku jest 3e-hydroksy-17a-oksa-D-homo-B-norandrost-5-en-17-on.The essence of the invention is 3e-hydroxy-17a-oxa-D-homo-B-norandrost-5-en-17-one.
Z kolei istotą sposobu według wynalazku jest to, że do podłoża odpowiedniego dla wzrostu grzybów strzępkowych wprowadza się zawiesinę komórek Beauvera bassiana KCH1065 i hodowlę prowadzi się przez kilka dni przy stałym wstrząsaniu w temperaturze 20-26°C. Po upływie co najmniej 48 godzin do hodowli dodaje się substrat o wzorze 1, którym jest octan B-nor-dehydroepiandrosteronu, rozpuszczony w rozpuszczalniku organicznym mieszającym się z wodą. Transformację prowadzi się w temperaturze od 20°C do 26°C, przy ciągłym wstrząsaniu, co najmniej 4 doby. Uzyskane roztworyIn turn, the essence of the method according to the invention is that a suspension of Beauver bassiana KCH1065 cells is introduced into a medium suitable for the growth of filamentous fungi and the cultivation is carried out for several days under constant shaking at a temperature of 20-26 ° C. After at least 48 hours, the substrate of formula I is added to the culture, which is B-nor-dehydroepiandrosterone acetate, dissolved in a water-miscible organic solvent. The transformation is carried out at a temperature of 20 ° C to 26 ° C with continuous shaking for at least 4 days. Obtained solutions
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL429380A PL239843B1 (en) | 2019-03-25 | 2019-03-25 | 3β-Hydroxy-17a-oxa-D-homo-B-norandrost-5-en-17-one and method of preparing 3β-hydroxy-17a-oxa-D-homo-B-norandrost-5-en-17-one |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL429380A PL239843B1 (en) | 2019-03-25 | 2019-03-25 | 3β-Hydroxy-17a-oxa-D-homo-B-norandrost-5-en-17-one and method of preparing 3β-hydroxy-17a-oxa-D-homo-B-norandrost-5-en-17-one |
Publications (2)
Publication Number | Publication Date |
---|---|
PL429380A1 PL429380A1 (en) | 2020-10-05 |
PL239843B1 true PL239843B1 (en) | 2022-01-17 |
Family
ID=72669272
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL429380A PL239843B1 (en) | 2019-03-25 | 2019-03-25 | 3β-Hydroxy-17a-oxa-D-homo-B-norandrost-5-en-17-one and method of preparing 3β-hydroxy-17a-oxa-D-homo-B-norandrost-5-en-17-one |
Country Status (1)
Country | Link |
---|---|
PL (1) | PL239843B1 (en) |
-
2019
- 2019-03-25 PL PL429380A patent/PL239843B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
PL429380A1 (en) | 2020-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mehta et al. | Enantioselective total synthesis of epoxyquinone natural products (−)-phyllostine,(+)-epoxydon,(+)-epiepoxydon and (−)-panepophenanthrin: access to versatile chiral building blocks through enzymatic kinetic resolution | |
PL239843B1 (en) | 3β-Hydroxy-17a-oxa-D-homo-B-norandrost-5-en-17-one and method of preparing 3β-hydroxy-17a-oxa-D-homo-B-norandrost-5-en-17-one | |
JP2564576B2 (en) | Brassinosteroid derivative and plant growth regulator using the same | |
PL237709B1 (en) | 3β-Hydroxy-5α-chloro-6,19-oxidoandrostan-17-one and method of preparation of 3β-hydroxy-5α-chloro-6,19-oxidoandrostan-17-one | |
WO2016135749A1 (en) | Diosgenin acetate-isoxazole derivatives, process for preparation thereof and their antifungal activity | |
PL237135B1 (en) | 3β,17α-Dihydroxy-5α-chloro-6,19-oxidoandrostane and method of preparation of 3β,17α-dihydroxy-5α-chloro-6,19-oxidoandrostane | |
PL237710B1 (en) | 3β-Hydroxy-5α-chloro-6,19-oxidoandrostan-17-one and method of preparation of 3β-hydroxy-5α-chloro-6,19-oxidoandrostan-17-one | |
PL239564B1 (en) | 3β-Hydroxy-5α-chloro-17a-oxa-D-homo-6,19-oxidoandrostan-17-one and method of preparation of 3β-hydroxy-5α-chloro-17a-oxa-D-homo-6,19-oxidoandrostane-17-one | |
PL239563B1 (en) | 3β-Hydroxy-5α-chloro-17a-oxa-D-homo-6,19-oxidoandrostan-17-one and method of preparation of 3β-hydroxy-5α-chloro-17a-oxa-D-homo-6,19-oxidoandrostane-17-one | |
PL237711B1 (en) | 3β-Hydroxy-5α-chloro-6,19-oxidoandrostan-17-one and method of preparation of 3β-hydroxy-5α-chloro-6,19-oxidoandrostan-17-one | |
PL237134B1 (en) | 3β,11α-Dihydroxy-5α-chloro-6,19-oxidoandrostan-17-one and method of preparation of 3β,11α-dihydroxy-5α-chloro-6,19-oxidoandrostan-17-one | |
PL236834B1 (en) | 3β,11α-Dihydroxy-5α-chloro-17a-oxa-D-homo-6,19-oxidoandrostan-17-one and method of preparation of 3β,11α-dihydroxy-5α-chloro-17a-oxa-D-homo-6,19 oksidoandrostan-17-one | |
PL226320B1 (en) | Method for producing 3�-hydroxy-17a-oxa-D-homo-androst-5-en-17-one | |
PL239842B1 (en) | Method of preparing 19-nortestolactone | |
PL235286B1 (en) | Method for producing 3β-hydroxy-17a-oxa-D-homo-androst-5-en-7,17-dione | |
PL242333B1 (en) | 4'-Hydroxy-6-methylene-O-β-D-(4'-O-methylglucopyranosyl)-flavanone and method of preparation of 4'-hydroxy-6-methylene-O-β-D-(4'-O-methylglucopyranosyl)-flavanone | |
AU7327798A (en) | 4-aza-steroids | |
PL242335B1 (en) | 6-Hydroxymethyl-3'-O-β-D-(4'-O-methylglucopyranosyl)-flavanone and method of preparation of 6-hydroxymethyl-3'-O-β-D-(4'-O-methylglucopyranosyl)-flavanone | |
PL242334B1 (en) | 4'-Hydroxy-6-methyl-3'-O-β-D-(4'-O-methylglucopyranosyl)-flavanone and method of preparation of 4'-hydroxy-6-methyl-3'-O-β-D-(4'-O-methylglucopyranosyl)-flavanone | |
PL228761B1 (en) | Method for producing 3-dihydroxy-17a-oxa-D-homo-androst-5-en-17-one | |
PL242469B1 (en) | 3 ', 4'-Dihydroxy-6-hydroxymethylflavanone and 3', 4'-dihydroxy-6-hydroxymethylflavanone production method | |
PL242468B1 (en) | Method for producing 6-Methyl-4'-O-β-D- (4 '- O-methylglucopyranosyl) -flavanone | |
PL241537B1 (en) | 15α-Hydroxyoxandrolone and process for the preparation of 15α-hydroxyoxandrolone | |
PL232297B1 (en) | 3β, 11α-dihydroxyandrost-5-en-7,17-dione and method for producing new 3β, 11α-dihydroxyandrost-5-en-7,17-dione | |
PL215117B1 (en) | Method for production of 3�, 11?-dihydroxy-17a-oxa-D-homo-5?-androstan-17-one |